Australia is within reach of achieving its pledge to end new HIV transmissions by 2020.
The HIV prevention drug Truvada (PrEP) will be listed on the Pharmaceutical Benefits Scheme from this Sunday, moving Australia closer to achieving its goal of ending new HIV transmissions by 2020.
In this March 18, 2011 photo, Cassidy Hempel waved at hospital staff as she was being treated for a rare disorder. Her mother Chris, left, fought to gain permission for an experimental drug.
AP Photo/Marcio Jose Sanchez
Congress has sent a bill to the White House. It gives terminally-ill patients more false hope than chances for a cure.
Are research nonprofits holding up their end of the tax-exempt bargain?
Holding patents can be a lucrative and powerful position to be in. Here's a proposal for how nonprofit patent holders can do more for the common good – and live up to their end of the tax break bargain.
The high cost of cancer drugs in South Africa has come under the spotlight with an investigation by the Competition Commission in the country.
Thalidomide was used by the pregnant women – the population that turned out to be most vulnerable to its risks.
Thalidomide's manufacturer, Chemie Grünenthal, marketed the drug as safe for pregnant women despite reports it was causing malformations in newborns. Why such blatant denial?